Table 2 BRIDGE-CRC trial measurements

 Height

X

 Weight^a

X

X

X

 Body composition (DXA)

X

X

 Systemic inflammation (hs-CRP)

X

X

X

 Circulating cytokines (GM-CSF, IL-2, IL-4, IL-6, IL-8, IL-10, TNFα, and IFNγ)

X

X

X

 Glucose, mg/dL

X

X

X

 Insulin, uIU/mL

X

X

X

 Hemoglobin A1c, %

X

X

X

 HOMA-IR (calculated from glucose and insulin)

X

X

X

Blood pressure, mmHg

X

X

 VioScreen food frequency questionnaire (FFQ)

X

X

 24-h diet recall (two per timepoint) (ASA24)

X

X

X

 MEPA-III MedDiet screener

X

X

X

Medication use

X

X

X

Physical activity (steps per day, FitBit)

X

X

Microbiota composition (16S rRNA)

X

X

X

Predicted gene abundance, metabolic pathways, and microbial network analysis

X

X

X

Quantification of the following genes via PCR: dissimilatory sulfite reductase A (pandsrA), B. wadsworthia-specific dsrA, 16S rRNA, Desulfovibrio spp.-specific 16S rRNA, BA 7α-dehydratase from C. scindens, butyryl-CoA transferase gene (BcoA)

X

X

X

Fecal short chain fatty acids (uM) (e.g., butyrate, acetate, and propionate)

X

X

X

Fecal and circulating bile acids (uM) (i.e., total BAs, total unconjugated BAs, taurine- and glycine-conjugated BAs, and CA, CDCA, LCA, and DCA)

X

X

X

Exfoliated intestinal cell gene expression analysis

X

X

X

 Demographics

X

 Health history, including bowel health

X

X

 Sleep quality

X

X

 Food away from home

X

X

  Discrimination

X

  Food security

X

X

  Depressive symptoms

X

X

  Stress

X

X

  Recent trauma

X

X

  Anxiety

X

X